Technavio has announced the release of their research report on the global testicular cancer drugs market for the forecast period 2019-2023. This testicular cancer drugs market analysis report segments the market by type (non-seminoma and seminoma) and geography (Asia, Europe, North America, and ROW).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190129005652/en/
Technavio has released a new market research report on the global testicular cancer drugs market for the period 2019-2023. (Graphic: Business Wire)
Global testicular cancer drugs market size will grow at a CAGR of more than 4% during 2019-2023. The market has been witnessing advances in diagnostic methods for testicular cancer. SALL4 reactivation is a suitable diagnostic method for testicular cancer. Further staging is another test, which is performed to determine the extent of spread of cancer to other parts of the body. There are other methods, which are used for the diagnosis of testicular cancer, including ultrasound and biopsy. The availability of diagnostic methods for testicular cancer is anticipated to boost the testicular cancer drugs market.
Availability of combination therapies
Combined drug therapy is more effective when compared with single-drug therapy, and it has been witnessed that the survival rate in patients with testicular cancer increased enormously with the use of combination therapies. The researchers have been concentrating on the development of new combination therapies owing to their effectiveness in treating testicular cancer. The treatment of stage IIA seminomas and stage IIB seminomas can be done using either four cycles of etoposide, ifosfamide, and cisplatin or three cycles of bleomycin, etoposide, and cisplatin. The researchers are focused on the development of new combination therapies because of their effectiveness in treating testicular cancer.
Request for a FREE sample and get selected illustrations, table of contents, list of exhibits, and example pages from this report.
“North America and Europe are expected to grow at a faster rate than the global CAGR over the next five years. The factors that are promoting the growth of the market in these regions are the rise in prevalence of testicular cancer and initiatives by several organizations to increase awareness and educate the public about the disease,” says an analyst at Technavio.
The prevalence of testicular cancer has increased across the globe. Testicular cancer is prevalent in men that have an undescended testicle, abnormal testicle development, and a family history of cancer. This high prevalence of testicular cancer can be attributed to environmental pollutants. Additionally, estrogenic activity results in hormonal disruption and is responsible for the gradually increasing incidence of testicular cancer. Thus, there is an increased need for initiatives to raise awareness regarding testicular cancer, which will further boost the growth of testicular cancer drugs market.
View a snapshot of the report for a more detailed overview of the market and the segmentation covered in this report
This testicular cancer drugs industry research report provides an in-depth analysis of the primary drivers, upcoming trends, and challenges that will impact market growth over the forecast period. The report analyzes the competitive landscape and offers details on several testicular cancer drugs products manufacturers including –
- Baxter
- Bristol-Myers Squibb
- Eli Lilly
- Pfizer
- Teva Pharmaceutical
Some of the key topics covered in the report include:
Market Landscape
- Market ecosystem
- Market characteristics
- Market segmentation analysis
Market Sizing
- Market definition
- Market size and forecast
Five Forces Analysis
Market Segmentation
Geographical Segmentation
- Regional comparison
- Key leading countries
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. Technavio’s report library consists of more than 10,000 reports covering 800 technologies, spanning across 50 countries. Their client base comprises enterprises of all sizes, including more than 100 Fortune 500 companies.
Please contact our media team at media@technavio.com for more information
View source version on businesswire.com: https://www.businesswire.com/news/home/20190129005652/en/
